HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fragrance Creators Association: Risk-Based Assessments For Ingredients Aren't Broken

Executive Summary

With cosmetics industry readying to confront wave of hazard-based regulations in Europe, Fragrance Creators Association publishes white paper to shore up advocacy efforts supporting risk-based assessments.

You may also be interested in...



California Eyeing More Cosmetic Ingredient Bans To Align With EU

“In the absence of protective federal action, states must take charge and get toxic chemicals out of our everyday products,” says Scott Faber, senior VP of government affairs at the Environmental Working Group. EWG is sponsoring AB 496, proposed on 7 February by Democratic Assemblymember Laura Friedman.

EU Reg Consultant On CLP Revisions: Take A Breath, Cost It Out, Consider ‘Lobbying And Pushing Back’

Louise Witter of UK-based Chemical Legislation Professionals spoke with HBW Insight ahead of the European Commission’s 19 December adoption of a proposal to revise the CLP by introducing new hazard classes, including for endocrine disruptors.

‘Monumentally Impactful Rulemaking’: Personal Fragrance Must Contend With California VOC Reset

The California Air Resources Board’s proposed amendments to slash VOC limits in consumer products are headed for effect in April. In its Final Statement of Reasons, CARB holds that sharply reduced VOC limits for personal fragrance products are feasible over coming years, despite deep skepticism from an industry pointing to evidence to the contrary.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153405

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel